An efficient *in vivo*-inducible CRISPR interference system for group A *Streptococcus* genetic analysis and pathogenesis studies

Elisabet Bjånes,[1] Alexandra Stream,[1] Axel B. Janssen,[2] Paddy S. Gibson,[2] Afonso M. Bravo,[2] Samira Dahesh,[1] Jonathon L. Baker,[3,4] Andrew Varble,[5] Victor Nizet,[1,6] Jan-Willem Veening[1,2]

AUTHOR AFFILIATIONS See affiliation list on p. 15.

ABSTRACT While genome-wide transposon mutagenesis screens have identified numerous essential genes in the significant human pathogen *Streptococcus pyogenes* (group A *Streptococcus* or GAS), many of their functions remain elusive. This knowledge gap is attributed in part to the limited molecular toolbox for controlling GAS gene expression and the bacterium's poor genetic transformability. CRISPR interference (CRISPRi), using catalytically inactive GAS Cas9 (dCas9), is a powerful approach to specifically repress gene expression in both bacteria and eukaryotes, but ironically, it has never been harnessed for controlled gene expression in GAS. In this study, we present a highly transformable and fully virulent serotype M1T1 GAS strain and introduce a doxycycline-inducible CRISPRi system for efficient repression of bacterial gene expression. We demonstrate highly efficient, oligo-based single guide RNA cloning directly to GAS, enabling the construction of a gene knockdown strain in just 2 days, in contrast to the several weeks typically required. The system is shown to be titratable and functional both *in vitro* and *in vivo* using a murine model of GAS infection. Furthermore, we provide direct *in vivo* evidence that the expression of the conserved cell division gene *ftsZ* is essential for GAS virulence, highlighting its promise as a target for emerging FtsZ inhibitors. Finally, we introduce SpyBrowse (https://veeninglab.com/SpyBrowse), a comprehensive and user-friendly online resource for visually inspecting and exploring GAS genetic features. The tools and methodologies described in this work are poised to facilitate fundamental research in GAS, contribute to vaccine development, and aid in the discovery of antibiotic targets.

IMPORTANCE While group A *Streptococcus* (GAS) remains a predominant cause of bacterial infections worldwide, there are limited genetic tools available to study its basic cell biology. Here, we bridge this gap by creating a highly transformable, fully virulent M1T1 GAS strain. In addition, we established a tight and titratable doxycycline-inducible system and developed CRISPR interference (CRISPRi) for controlled gene expression in GAS. We show that CRISPRi is functional *in vivo* in a mouse infection model. Additionally, we present SpyBrowse, an intuitive and accessible genome browser (https://veeninglab.com/SpyBrowse). Overall, this work overcomes significant technical challenges of working with GAS and, together with SpyBrowse, represents a valuable resource for researchers in the GAS field.

KEYWORDS group A *Streptococcus*, CRISPRi, SpyBrowse, infectious disease, *Streptococcus pyogenes*, genetic toolbox

*S*treptococcus pyogenes, also known as group A *Streptococcus* (GAS), is a bacterium commonly present in the throat and on the skin (1, 2). This pathogen is notorious for causing strep throat and impetigo, accounting for approximately 700 million non-invasive infections each year (3–5). However, GAS can also lead to serious invasive diseases,

including necrotizing fasciitis and streptococcal toxic shock syndrome, resulting in over 150,000 deaths annually (4). Additionally, GAS is the immunological trigger for acute rheumatic fever and rheumatic heart disease, causing substantial death and disability in many developing countries. Despite rising GAS resistance to certain antibiotic classes, the pathogen has fortunately remained susceptible to penicillin and other β-lactam agents (6).

There is presently no commercially available vaccine to protect against GAS infection (7). GAS presents a challenge for vaccine antigen selection due to the variability in the abundant surface-exposed M protein with over 230 *emm* types circulating globally (8). The most common *emm* type, M1, is a major contributor to GAS global epidemiology and is particularly prominent in severe, invasive infections (9). The search for new GAS antibiotic targets and vaccine candidates is hindered by a knowledge gap in fundamental GAS biology, partly because M1-type GAS strains are exceptionally challenging to manipulate genetically (10, 11). In this study, we present a toolbox for GAS genetic engineering, utilizing the hard-to-transform and clinically relevant M1T1-type strain 5448 (NV1) as a model (1, 12). We selected strain 5448 since it is commonly used, and we reckoned that if our approaches work in this strain, they are highly likely to also work in generally easier-to-work-with GAS strains. This toolbox should be generally applicable to GAS and related bacteria, encompassing protocols for recombineering using Golden-Gate-assembled linear DNA, oligo-based single guide RNA (sgRNA) cloning, a titratable doxycycline-inducible promoter, and CRISPR interference (CRISPRi) effective both *in vitro* and *in vivo* in a murine GAS infection model.

Additionally, we present SpyBrowse, an intuitive and accessible genome browser (https://veeninglab.com/SpyBrowse), based on JBrowse 2 (13), a graphical and user-friendly interface to explore the GAS genomic landscape with direct linking to UniProt (14) and other useful resources such as PaperBlast (15). Overall, this work overcomes significant technical challenges of working with GAS, facilitating genetic engineering and targeted gene knockdowns to advance our insights into the physiology and cell biology of this preeminent human bacterial pathogen.

RESULTS

Improved transformability of GAS M1T1 strain 5448 by mutating *hsdR*

GAS5448, a widely used strain in fundamental research, serves as a clinical representative of the globally distributed M1T1 serotype associated with severe invasive infections. While 5448 has been effectively employed in murine models of GAS infection (16, 17), its genetic manipulation poses challenges, with even the construction of transposon mutant libraries proving highly difficult (10, 11, 18). To enhance GAS 5448 transformation efficiencies while retaining full virulence, we targeted one of the major barriers to transformation—the HsdR restriction subunit of the conserved three-component Type I restriction-modification (RM) system, HsdRSM. *Hsd,* denoting host specificity of DNA, signifies how these Type I RM systems cleave intracellular (foreign) DNA with improper methylation patterns. Mutations in this system improve transformation efficiency in other GAS strains (19–22), but with potential pleiotropic consequences. For example, while the deletion of the entire *hsdRSM* system in serotype M28 GAS strain MEW123 boosted transformation efficiency, it concurrently reduced virulence in a murine model of infection (20). A spectinomycin marker-replacement mutant eliminating just the restriction subunit *hsdR* also increased transformation efficiency but led to partially methylated genomic DNA likely due to polar effects (20).

To address the above obstacles, we generated a mutant of *hsdR* in the wild-type (WT) GAS 5448 (strain NV1, Table 1) using an erythromycin resistance cassette. This cassette, previously demonstrated to provide selectable resistance at very low transcription levels without requiring an upstream promoter (23), was introduced using GoldenGate assembly combined with recombineering (Fig. 1A and B, strain NV28: *hsdR::ery*, see Materials and Methods for details). Single-Molecule Real Time (SMRT) sequencing (PacBio) confirmed the desired mutation in NV28, and the identical genomic DNA

TABLE 1 Plasmids and bacterial strains used in this study

Strain/plasmid	Relevant genotype[a]	Reference
S. pyogenes		
NV1	GAS 5448 serotype M1T1	(12)
NV2	NV1, *cat*, pAV488 (*cat*, recombineering plasmid)	This study
NV3	NV2, *cat*, *ery*, pAV488, Δ*hsdR*::*ery*	This study
NV4	NV3, *cat*, *ery*, *kan*, pAV488, Δ*hsdR*::*ery*, Δ*cas9*::*kan*	This study
NV6	NV1, *ery*, *tet*, Δ*hsdR*::*ery*, Δ*cas9*::P$_{tet}$-*dcas9*, *tetR*, *tetM*	This study
NV9	NV1, *cat*, pDC-sgRNA (P$_3$-*mCherry-sgRNA*, *cat*)	This study
NV19	NV6, *ery*, *tet*, *cat*, Δ*hsdR*::*ery*, Δ*cas9*::P$_{tet}$-*dcas9*, *tetR*, *tetM*, pDC-sgRNA-ftsZ (P$_3$-*sgRNA-ftsZ*, *cat*)	This study
NV22	NV6, *ery*, *tet*, *cat*, Δ*hsdR*::*ery*, Δ*cas9*::P$_{tet}$-*dcas9*, *tetR*, *tetM*, pDC-sgRNA-dnaA (P$_3$-*sgRNA-dnaA*, *cat*)	This study
NV25	NV6, *ery*, *tet*, *cat*, Δ*hsdR*::*ery*, Δ*cas9*::P$_{tet}$-*dcas9*, *tetR*, *tetM*, pDC-sgRNA-emm (P$_3$-*sgRNA-emm*, *cat*)	This study
NV26	NV6, *ery*, *tet*, *cat*, Δ*hsdR*::*ery*, Δ*cas9*::P$_{tet}$-*dcas9*, *tetR*, *tetM*, pDC-sgRNA-control (P$_3$-*sgRNA-control*, *cat*)	This study
Escherichia coli		
MC1061	F- Δ(*ara-leu*)7697 [*araD139*]B/r Δ(*codB-lacI*)3 *galK16 galE15* λ- e14- *mcrA0 relA1 rpsL150*(StrR) *spoT1 mcrB1 hsdR2*(r-m+)	MClab
Plasmids		
pDC123	*cat*, *phoZ*	(24)
pDC-sgRNA	P$_3$-*mCherry-sgRNA*, *cat*	This study

[a]*cat*, chloramphenicol resistance marker; *ery*, erythromycin resistance marker; *tetM*, tetracycline resistance marker; and *kan*, kanamycin resistance marker.

methylation pattern to NV1 validating the absence of polar effects from the erythromycin cassette replacement. Global DNA methylation patterns' analysis suggested that the MTase activity of the HsdRSM system of GAS strain 5448 methylates adenines at position 3 in the motifs 5′-GCANNNNNNTTAA′3′ and 5′-TTAANNNNNNTGC′3′, with all 344 motifs in the NV1 genome methylated, consistent with the patterns observed in other M1 strains (21) (Fig. 1C).

Electroporation transformation efficiency with replicative plasmid pDC123 (24), lacking a putative HsdR restriction site, remained as efficient in the *hsdR*::*ery* mutant as in the WT. However, when strain NV28 was transformed with replicative plasmid pDC-sgRNA (see below, Fig. 2E), containing a single HsdR site, transformation efficiencies were more than 60-fold higher than transforming pDC-sgRNA to WT NV1 (Fig. 1D). Consequently, the newly constructed GAS M1T1 5448-derived *hsdR*::*ery* mutant not only allows for increased transformation efficiencies with foreign DNA containing HsdR motifs but may also serve as a valuable genetic background for future studies. Moreover, the virulence of the strain harboring the *hsdR*::*ery* cassette was indistinguishable from its WT parent strain (see below, Fig. 5C).

The long-read genome-sequenced NV1 strain was compared to the published 5448 reference genome, which was generated by Illumina short-read sequencing (26), revealing a large inversion of 1,475,033 base pairs. This structural variant is flanked by two ISAs1-like element IS1548 family transposase genes, which typically harbor terminal inverted repeats (27). The two transposase genes are oriented in opposing directions and exhibit two single nucleotide polymorphisms. It is highly probable that the short-read approach used in the original 5448 genome project contributed to an inaccurate genome assembly. In addition, NV1 contains 6,323 additional bases compared to 5448, and several Single nucleotide polymorphisms (SNPs) mainly attributed to the transposase genes (see Materials and Methods). Therefore, we propose using the genome assembly presented here for GAS studies involving strain 5448 NV1 (GenBank accession CP140117.2).

Replacing wild-type GAS *cas9* with a doxycycline-inducible dead *cas9* (*dcas9*)

CRISPRi has emerged as a powerful approach for evaluating the functionality of both essential and non-essential genes across a wide range of bacteria (28–31). This gene-silencing technique employs a catalytically inactive version of the GAS Cas9 protein (dCas9) and a single guide RNA. The dCas9-sgRNA complex binds via complementary base pairing of the spacer sequence in the sgRNA to a specific genomic DNA sequence

FIG 1 Golden Gate assembly and recombineering to create a highly transformable *hsdR* mutant in M1T1 GAS strain 5448. (A) Schematic representation of the genomic organization of the *hsdRSM* locus in WT GAS strain M1 5448 (NV1). Gene annotations were made by Prokka (25). (B) Three PCRs were performed each containing unique *Bsa*I restriction sites that allow for scarless Golden Gate assembly of a linear fragment in which *hsdR* is replaced by an erythromycin resistance cassette (*ery*). PCR 1 contains 1,392 bp upstream of *hsdR* (including the *garK* gene and excluding the start codon of *hsdR*), PCR 2 contains the 785 bp promoterless and terminatorless *ery* cassette (23) flanked by *Bsa*I sites, while PCR 3 contains a 1,238 bp downstream region of *hsdR* (including its stop codon and *hsdS*). After Golden Gate assembly with *Bsa*I and T4 ligase (see Materials and Methods), the resulting 3,383-bp ligation product was purified and directly used to transform electrocompetent NV2 (NV1 + pAV488) cells that were grown with 1 mM of β-D-1-thiogalactopyranoside to induce the recombineering system present on plasmid pAV488 resulting in strain NV3 (NV2, *hsdR::ery*). Recombineering of GAS using pAV488 is described in more detail elsewhere (Andrew Varble, unpublished data). Strain NV3 was plasmid cured resulting in strain NV28 (NV1, *hsdR::ery*). The genomic organization of the *hsdRSM* locus in strain NV28 (*hsdR::ery*) is shown. (C) Methylation motifs identified in strains NV1, NV28, and NV6 using SMRT sequencing (see Materials and Methods for details). (D) Transformation efficiencies of WT GAS 5448 (NV1) and the *hsdR::ery* mutant (NV28) are shown. Left: strains were transformed with 140 ng (~50 fmol) of plasmid pDC123 (24) that does not contain an HsdR-motif. Right: strains were transformed with 247 ng (~95 fmol) of plasmid pDC-sgRNA (see Fig. 2C) that contains a single HsdR-motif. Each dot represents a replicate, and a Kolmogorov-Smirnov test was used to calculate statistically significant differences between the two strains (**P value < 0.005).

located beside a protospacer adjacent motif. This binding effectively halts the transcription of the target gene and genes within the same operon (Fig. 2A) (32, 33). Curiously, while GAS Cas9 is frequently utilized in CRISPRi across various bacteria, as far as we are aware, CRISPRi has not been applied to GAS (34). Our objective in this study is to close this gap and introduce CRISPRi as a valuable tool for investigating gene function in GAS.

An optimal CRISPRi system should tightly regulate the expression of a dCas9. However, the selection of suitable inducible promoters for GAS has been limited. The most commonly used system involves a tetracycline-inducible promoter adapted from the Gram-negative bacterium *Escherichia coli* (35, 36). Unfortunately, this system has been reported to exhibit either leakiness or a narrow induction range in GAS (36). In a previous study, we developed a tetracycline, anhydrotetracycline, and doxycycline-inducible CRISPRi system with a highly dynamic range in *Streptococcus pneumoniae*. This was achieved by codon optimizing *E. coli tetR,* combined with the selection and counterselection of random promoter libraries containing *tetO* operators (23, 37). Given the similar codon usage between GAS and *S. pneumoniae*, we hypothesized that this TetR-based system could also function effectively in GAS. An additional advantage of this TetR-based system is the excellent tissue penetration of doxycycline (doxy) (38). Our prior work demonstrated the successful delivery of doxy through mouse chow or direct intraperitoneal (I.P.) injection to induce pneumococcal constructs in various mouse body/tissue niches, including the blood and lungs (23, 37, 39).

To mitigate potential crosstalk with the intrinsic Cas9-CRISPR system, we strategically chose the WT GAS *cas9* locus as the genomic integration site for the stable introduction of the inducible *dcas9* cassette. Using Golden Gate assembly in conjunction with recombineering (see Materials and Methods), we first replaced the native *cas9* locus, inclusive of the tracrRNA and the CRISPR spacer array locus, with a kanamycin resistance marker (*kan*), resulting in strain NV4 (Fig. 2B). Next, we replaced the *kan* marker of strain NV4 with the *tetM-tetR-Ptet-dcas9* cassette from *S. pneumoniae* strain VL3469 (37). This cassette imparts tetracycline/doxycycline resistance via the *tetM* marker and positions *dcas9* under the TetR-controlled *S. pneumoniae* P*tet* promoter (23). Finally, the strain underwent curing of the pAV488 recombineering plasmid, yielding strain NV6 (Fig. 2B). Whole-genome sequencing of strain NV6 verified the accurate introduction of all elements (SRA genome accession number SRX22828772).

Construction of Gram-positive replicative vector pDC-sgRNA enables efficient sgRNA cloning

Next, we designed a replicative vector tailored for direct sgRNA cloning in GAS. We replaced the *phoZ* reporter gene within the Gram-positive high-copy number (~24–90 copies per cell) rolling-circle replication pDC123 plasmid (24, 40) with an *mCherry* cassette flanked by the sgRNA scaffold sequence and Esp3I restriction sites. This configuration allows for Golden Gate assembly or direct ligation of sgRNA spacers using annealed oligonucleotides (Fig. 2C). This vector is also capable of replicating in *recA+* *E. coli* strains, such as MC1061, albeit at low copy numbers (~4 copies per cell) (40). In addition, we incorporated Illumina read 1 and read 2 sequences flanking the sgRNA scaffold to facilitate CRISPRi-seq (41). Notably, we included the +1 of the P3 promoter, ensuring that all cloned spacers initiate with an adenine nucleotide (41). This design promotes efficient transcription and prevents undesirable uridines at the 5′ end of the sgRNA (42). Finally, the vector contains a chloramphenicol resistance cassette (*cat*) for selection in GAS (Fig. 2C). To validate the functionality of the synthetic P3 promoter (43) in GAS, we transformed pDC-sgRNA into strain NV1, creating NV9. Bacterial examination by fluorescence microscopy revealed strong and uniform mCherry expression in all cells (Fig. 2D), confirming the functionality of the P3 promoter in GAS. Given that pDC-sgRNA features the Gram-positive pLS1/pJS3 origin, it is anticipated to be functional across a broad range of Gram-positive bacteria, including but not limited to *Lactococcus lactis*, *Bacillus subtilis*, *S. pneumoniae*, *Enterococcus faecalis,* and group B *Streptococcus*.

An established pipeline generates unique genome-wide sgRNA spacers for GAS 5448

With the establishment of an inducible *dcas9* strain and an sgRNA expression system for GAS, we systematically designed sgRNA spacer sequences targeting every annotated genetic feature of the GAS 5448 genome using our previously established pipeline

FIG 2 Development of a doxycycline-inducible CRISPRi system for use in group A *Streptococcus*. (A) Schematic representation of CRISPRi. An sgRNA encoding a 20 nt spacer region targets dCas9 to the non-template strand containing a protospacer adjacent motif (PAM) on the GAS *ftsZ* locus. Transcription elongation by RNA polymerase (RNAP) is consequently hampered leading to reduced levels of FtsZ in the cell when dCas9 is induced. (B) Schematic representation of the genomic organization of the *cas9* locus in wild-type GAS strain 5448 (NV1), in strain NV4 (*cas9::kan*) and strain NV6 (*cas9::tetM*, *tetR*, Ptet-*dcas9*). (C) Schematic representation of sgRNA cloning vector pDC-sgRNA. (D) Strain NV9 (NV1, pDC-sgRNA) was grown in Todd Hewitt broth containing 2 µg/mL of chloramphenicol at 37°C, and exponentially growing cells were imaged by differential interference contrast (DIC) and fluorescence microscopy. Scale bar: 2 µm. (E) Oligo-based sgRNA cloning in pDC-sgRNA. Plasmid pDC-sgRNA is cut with Esp3I (or its isoschizomer BsmBI), and its resulting sticky ends are shown. Two complementary oligos of each 24 nt long that include a 20-bp spacer sequence are annealed, phosphorylated, ligated, and electroporated to competent GAS (see Materials and Methods). As an example, the two oligos used to clone the sgRNA targeting GAS *ftsZ* are shown (for oligo design, see Table S1). Successful clones lost the *mCherry* cassette and will be white on the plate instead of pink.

(41). The algorithm employed for spacer design only designs spacers that exclusively target the non-template strand (Fig. 2A) and considers factors such as specificity (to limit off-target effects), distance to the start site, and avoiding Esp3I/BsmBI restriction sites (41). Upon running the pipeline, a total of 1,823 unique spacers were generated, designed to target 1,879 out of 1,894 features on the NV1 (5448) genome as annotated by Prokka (25). Suitable spacers could not be identified for 15 genetic elements. Note that certain designed sgRNAs may target more than one genetic element if that element is present in multiple copies (e.g., repeats, gene duplications, etc.). A comprehensive list of all designed sgRNAs is provided in Table S1.

SpyBrowse: *Streptococcus pyogenes* (GAS) genome browser

On the basis of the fully closed GAS NV1 genome (GenBank accession CP140117.2), in conjunction with automated genome annotation (see Materials and Methods), we have developed a new user-friendly genome browser named SpyBrowse, accessible at https://veeninglab.com/SpyBrowse. Based on JBrowse 2 (13), SpyBrowse empowers users to conveniently and flexibly search for their gene of interest using either its gene name or locus tag (Fig. 3A). Clicking on features reveals further information (Fig. 3B), including links to Uniprot (including subcellular location predictions and Alphafold protein structure predictions; Fig. 3C), NCBI protein entry (Fig. 3D), and PaperBlast (Fig. 3E). In addition, SpyBrowse incorporates a track displaying all designed sgRNAs from Table S1.

CRISPRi can be used to tunably repress GAS gene expression

To assess the effectiveness of CRISPRi in downregulating the expression of essential genes in GAS, we targeted *dnaA*, which encodes the conserved replication initiator in bacteria, and *ftsZ*, encoding the conserved tubulin-like cell division protein FtsZ, which is essential for cell division. FtsZ is a component of the highly conserved division and cell wall (*dcw*) genomic cluster (44). Due to the anticipated polar effects of CRISPRi, it is expected that targeting *ftsZ* will also impact the transcription of other members of the *dcw* cluster. To construct each sgRNA plasmid, the design outlined in Table S1 was used, and complementary oligos were synthesized for each target. These oligos were annealed, phosphorylated, and ligated in Esp3I-digested pDG-sgRNA (Fig. 2C and E). Additionally, a control sgRNA was included, containing a random 20-bp sequence (5′-CATACAAGTCGATAGAAGAT-3′) that does not match any region in the GAS NV1 5448 genome. The ligation mixtures were directly used to transform electrocompetent GAS NV6 cells (see Materials and Methods). Correct clones were cultured in Todd Hewitt broth (THB) within microtiter plates, and the optical density was measured every 10 min. As depicted in Fig. 4A, the induction of dCas9 by increasing the concentrations of doxycycline (doxy) resulted in reduced growth with the *dnaA* and *ftsZ* sgRNAs but not with the control sgRNA. Note that at concentrations of 50 ng/mL of doxy, a reduction in growth is also observed for the control strain.

To confirm the specific targeting of *dnaA* and *ftsZ* by the designed sgRNAs, cells were grown in the presence or absence of 20 ng/mL of doxy for 3 h and imaged by microscopy. As anticipated, repression of *dnaA* expression by CRISPRi resulted in cell chaining, with numerous anucleate cells indicative of a failure to initiate DNA replication (Fig. 4B). Targeting *ftsZ* led to a distinct block in cell division, resulting in enlarged cells (Fig. 4B). These findings collectively show that the CRISPRi system developed for GAS in this study is titratable, specific, and suitable for studying essential genes.

CRISPRi to deplete the expression of the M protein, a signature GAS virulence factor

To explore the applicability of the CRISPRi system described here for GAS in pathogenesis studies, we initially designed an sgRNA targeting the *emm* gene, encoding the M-protein. As shown in Fig. 5A, the growth of strain NV25 (NV6 + pDC-sgRNA-*emm*) was not perturbed by the induction of dCas9 with doxy *in vitro*. Flow cytometry analysis, using an

FIG 3 SpyBrowse is available at https://veeninglab.com/SpyBrowse. (A) A screenshot of the *emm* locus as shown in SpyBrowse. In the left pane, tracks can be turned on/off. In the right pane, the genome can be browsed by dragging the mouse to the left or right, zooming in and out, or searched on gene name and/or locus tags (e.g., Spy1719 or U2W45_08500 for *emm*). Annotated features such as genes, rRNAs, and tRNAs are displayed. The designed spacer targeting the non-template strand of *emm* (JFONFGPK_01746_gR1311f) is shown via the sgRNA track. (B) For each coding sequence, a context menu provides links to external resources, such as Uniprot (with Alphafold prediction), NCBI (with Blast function), and PaperBlast. (C) The predicted Alphafold structure of the M1 protein through the Uniprot link in SpyBrowse is shown. (D) The NCBI entry for the M1 protein is shown. (E) The Paperblast hits for the M1 protein are shown.

antibody specific to the M1T1 protein, revealed that NV25 induced with doxy exhibited approximately eightfold less surface-exposed M protein. This result underscores the precision and efficacy of the CRISPRi-based gene repression system developed for GAS (Fig. 5B).

CRISPRi targeting of *ftsZ* reveals contribution to *in vivo* GAS virulence

To assess whether the engineered GAS CRISPRi strain NV6 exhibits a comparable virulence profile to the WT 5448 NV1, we intraperitoneally infected outbred CD-1 mice with $1–3 \times 10^8$ colony-forming units (CFU) and monitored disease progression. As shown in Fig. 5C, no significant difference in mouse survival was observed, demonstrating that the replacement of the CRISPR locus with our CRISPRi cassette, as well as the *hsdR* mutation, had no discernable global impact on systemic virulence.

A notable strength of CRISPRi lies in its ability to assess the functionality of essential genes. FtsZ, a highly conserved, tubulin-like, essential cell division protein, represents an attractive target for an expanding list of antibiotic candidates (39, 45). Certain compounds, such as PC190723, are particularly intriguing as they exhibit potent FtsZ inhibitory activity without targeting eukaryotic tubulin (46). While *in vivo* studies have demonstrated the efficacy of several FtsZ inhibitors in clearing bacterial infections, and

FIG 4 Targeted repression of *dnaA* and *ftsZ* gene expression by CRISPRi in GAS. (A) Strains NV26 (NV6 + pDC-sgRNA-*control*), NV22 (NV6 + pDC-sgRNA-*dnaA*), and NV19 (NV6 + pDC-sgRNA-*ftsZ*) were grown in THB containing 2 µg/mL of chloramphenicol at 37°C. Exponentially growing cells were diluted to a start OD of 0.004 in a microtiter plate containing fresh THB with varying concentrations of doxycycline (doxy). The optical density at 595 nm was measured every 10 min. Each line is an average of three replicates with the standard deviation shown. For clarity, the optical density is plotted on a linear scale. (B) Strains NV22 and NV19 were grown in the presence or absence of 20 ng/mL of doxy, and after 3 h, cells were imaged by fluorescence microscopy. DAPI was used to stain the nucleoids and Nile red to stain the membrane. Scale bar: 2 µm. Arrows point to anucleate cells (sgRNA-*dnaA*) or cells with a block in division (sgRNA-*ftsZ*).

it is evident that *ftsZ* is essential *in vitro* (Fig. 4), direct confirmation of the essentiality of FtsZ or the *dcw* cluster has not been established to the best of our knowledge. CRISPRi was used to target *ftsZ* (and because of the polarity of CRISPRi, potentially other genes in the *dcw* cluster) *in vivo*. Doxy-treated or mock control mice were challenged I.P. with 1–3 × 10^8 CFU of GAS strain NV19 (NV6 + pDC-sgRNA-*ftsZ*) and monitored for disease progression. Doxycycline (25 µg for ~1 mg/kg of body weight) or vehicle control was administered I.P. 1 h before infection and 48 h post-infection. As shown in Fig. 5D, 80% of mice that received doxy survived after 14 days compared to only 30% of mock-treated mice (*P* = 0.0027, Mantel-Cox log-rank test). To ensure that bacterial clearance was not solely attributed to the doxy treatment, an additional control group of mice was infected with strain NV26 (NV6 + pDC-sgRNA-*control*), carrying a non-targeting control sgRNA. No statistically significant difference in survival was observed for this group (Fig. 5D).

DISCUSSION

GAS remains a predominant cause of bacterial infections worldwide. While significant strides have been made in understanding GAS physiology and its interactions with the host (1, 17), fundamental insights into its basic cell biology lag behind. Such knowledge is crucial for the development of vaccines and the identification of novel drug targets. The existing knowledge gap is largely attributed to the challenges in the genetic manipulation of pathogenic GAS strains and the absence of a modern molecular toolbox. Here, we bridge this gap by creating a highly transformable, fully virulent M1T1 GAS strain, establishing a titratable doxy/tetracycline/aTc-inducible system, and introducing CRISPRi for controlled gene expression in GAS.

By employing a non-polar *hsdR* mutant, sgRNAs can be directly cloned into GAS without the need for an *E. coli* intermediate. This streamlined approach makes it possible to obtain a specific gene depletion within days, as opposed to weeks or months (10). Utilizing readily available oligonucleotides, following the design outlined in Table S1, and using previously prepared electrocompetent NV6 cells (*hsdR::ery*, *cas9::tetM*, *tetR*,

FIG 5 Efficient depletion of M protein and *in vivo* CRISPRi in GAS. (A) Strain NV25 (NV6 + pDC-sgRNA-*emm*) was grown in THB containing 2 µg/mL of chloramphenicol at 37°C in microtiter plates in the presence of various concentrations of doxycycline. (B) Strains NV25 (sgRNA-emm), NV26 (sgRNA-control), and M protein knockout GAS M1T1 5448 were grown in THB to mid-logarithmic growth in the presence or absence of 20 ng/mL doxycycline. Bacteria were immunostained using M protein antisera and analyzed by flow cytometry as described in Materials and Methods. (C) Strains NV1 (wild-type GAS 5448) and NV6 (*cas9::tetM*, *tetR*, Ptet-*dcas9*, *hsdR::ery*) were grown in THB at 37°C, and $1–3 \times 10^8$ colony-forming units (CFU) were used to infect CD-1 mice IP (10 mice per group). Disease score and survival were followed for 14 days. There was no statistically significant (n.s.) difference in virulence between both strains (Mantel-Cox Log Rank test). (D) Strains NV26 (NV6 + pDC-sgRNA-*control*) and NV19 (NV6 + pDC-sgRNA-*ftsZ*) were grown in THB containing 2 µg/mL of chloramphenicol at 37°C, and $1–3 \times 10^8$ CFU were used to infect CD-1 mice IP (10 mice per group). Disease score and survival were followed for 14 days. Doxy-induced mice infected with NV19 showed a statistically significant increased survival (**$P = 0.0027$, Mantel-Cox Log Rank test).

Ptet-*dcas9*), a CRISPRi experiment can be conducted in as little as 3 days. Our system would also be easily transferable to other GAS strains by the addition of the phage anti-restriction protein Ocr, which protects incoming DNA from restriction by the HsdR system, thus negating the need to work in an *hsdR* mutant background (47). Importantly, we show that not only is this CRISPRi system functional *in vitro* but it can also be efficiently induced in a murine infection model, simply by administering doxy to the animal. Many GAS strains pick up *covS* mutations during *in vivo* infections, rendering them hypervirulent (48). Therefore, future *in vivo* CRISPRi experiments might be more efficient when performed in preexisting *covS* mutant strains. We also note that CRISPRi works by repressing transcription and not at the translational level, and due to its polar effects, genes downstream, or sometimes even upstream, might be affected when targeted by CRISPRi (32, 33, 49). Also, when targeting essential genes, *dcas9* mutants may be selected for, which needs to be taken into account when interpreting CRISPRi data (41).

The tools and methodologies outlined in this study can markedly enhance the throughput by which GAS research may be performed, and we foresee that genome-wide CRISPRi screens (CRISPRi-seq) will soon become feasible for GAS (41). CRISPRi and CRISPRi-seq offer advantages over existing TrAsh, Tn-seq, and TRADIS workflows for GAS (11, 18, 50) since they enable the examination of essential gene functions and the performance of titratable drug-gene interaction studies. Moreover, we anticipate that the Ptet-*dcas9* cassette and pDC-sgRNA plasmid system can be readily applied to other low GC-rich Gram-positive bacteria.

Annotation databases like SubtiWiki (51), EcoCyc (52), and PneumoBrowse (53) have significantly accelerated gene discovery, functional analysis, and hypothesis-driven studies for these bacteria. In this work, we introduce SpyBrowse (https://veenin-glab.com/SpyBrowse), a public domain resource enabling users to explore the newly assembled GAS *S. pyogenes* 5448 NV1 genome. SpyBrowse facilitates the inspection of encoded features, regulatory elements, repeat regions, and other valuable properties. It also provides information on sgRNA binding sites and links to useful bioinformatic resources such as Alphafold predictions (54) [via Uniprot (14)] and PaperBlast (15). SpyBrowse will undergo regular updates and is fully capable of incorporating various omics data and improved genome annotations, akin to the approach taken by PneumoBrowse (53). The methodologies presented in this study can serve as a roadmap for developing CRISPRi in other challenging-to-transform bacteria. Together with SpyBrowse, they should represent a valuable resource for researchers in the GAS field.

MATERIALS AND METHODS

Bacterial strains and culture conditions

All strains, plasmids, and primers used are listed in Table 1 and Table S2. All GAS strains in this study are derivatives of *S. pyogenes* 5448 (12) and are listed in Table 1. Strains were grown in liquid THB [Hardy Diagnostics (or Oxoid THB for Fig. 1D, right panel)] without aeration at 37°C. The β-D-1-thiogalactopyranoside (IPTG)-inducible promoter on pAV488 was activated with 1 mM IPTG (Sigma-Aldrich). Electrocompetent GAS cells were made by overnight growth in THB + 0.6% glycine followed by 1:10 dilution in fresh THB + 0.6% glycine. If required, 1 mM of IPTG was used to induce recombineering from pAV488 (Varble laboratory collection) when cells reached an OD_{600} of 0.15. At OD_{600} of 0.3, cells were centrifuged (4,000 rpm, 10 min, 4°C) and washed four times with 0.625 M sucrose before resuspending in 20% glycerol and stored at −80°C in 50 µL aliquots. For electroporation, DNA was added to one 50 µL aliquot of electrocompetent cells on ice for 5 min before transferring to a 1 mm electroporation cuvette (Genesee Scientific). After electroporation (Eppendorf 2510, 1.7 kV), cells were incubated in THB + 0.25 M sucrose for 2 h before overnight antibiotic selection on THA (37°C). When appropriate, the medium was supplemented with the following antibiotics: chloramphenicol (2 µg·mL^{-1}), erythromycin (0.5 µg·mL^{-1}), kanamycin (400 µg·mL^{-1}), and tetracycline (0.5 µg·mL^{-1}). Genomic GAS DNA was prepared using the Zymo Quick-DNA Fungal/Bacterial Miniprep Kit (4 mL of overnight culture was used as input). We note that some of the GAS strains engineered here contain an erythromycin resistance cassette. Since macrolide antibiotics are sometimes prescribed to treat GAS infections in individuals that have a penicillin allergy (all GAS strains described here are fully penicillin susceptible), we urge the community to only use these strains within appropriate biosafety conditions. We also note that in the unlikely event that someone with a penicillin allergy gets a GAS infection caused by one of these erythromycin-resistant strains, they can be safely treated with cephalexin or cefadroxil as all reported strains here are fully susceptible to these antibiotics.

Plasmid pDC-sgRNA was made in *E. coli* strain MC1061 (MClab) grown in LB medium at 37°C with aeration; 5 µg·mL^{-1} chloramphenicol was added when appropriate.

Recombineering and plasmid and strain construction

Recombineering plasmid pAV488 (Varble laboratory collection) was transformed by electroporation into wild-type 5448 (strain NV1) selecting on chloramphenicol, resulting in strain NV2 (Table 1). Next, the recombineering enzymes Gam, ERF recombinase, and single-stranded DNA-binding protein encoded on pAV488 were induced with 1 mM of IPTG, and cells were made electrocompetent and stored at −80°C. To generate an *hsdR* replacement mutant, an erythromycin cassette without promoter and terminator

but with its own RBS was amplified by PCR using primers ONV31/ONV32 (Table S2) using the chromosomal DNA of strain VL4321 (55) as a template. The *hsdR* upstream and downstream regions were amplified using the chromosomal DNA of strain NV1 as a template using primers ONV29/ONV30 and ONV33/ONV34, respectively (Fig. 1). The three PCR fragments were purified (Zymo DNA Clean and Concentrator kit: "Zymo kit") and used in a 1:1:1 molar ratio Golden Gate assembly reaction with BsaI (NEB) and T4 ligase (NEB) for 50 cycles of 1.5 min at 37°C followed by 3 min at 16°C. Enzymes were inactivated at 80°C for 10 min. The assembly was purified (Zymo kit), and 1 µL was used as a template in a PCR using primers ONV29/ONV34. The resulting 3,431-bp fragment was purified (Zymo kit), and 10 µL was used to transform electrocompetent NV2 cells. Erythromycin-resistant colonies were selected and used for further analysis, resulting in strain NV3 (*hsdR::ery*, pAV488). Strain NV3 was cured from plasmid pAV488 by growing it overnight in THB with 1 mM IPTG (without chloramphenicol) and restreaking single colonies, resulting in strain NV28 (*hsdR::ery*).

Strain NV4 (*hsdR::ery*, *cas9::kan*, pAV488) was made by amplifying approximately 1 kb upstream and downstream of the *cas9* locus (Fig. 2B) using primers ONV1/ONV2 and ONV5/OV6, respectively, using chromosomal DNA of strain NV1 as a template. A kanamycin resistance cassette including promoter and terminator was amplified from plasmid pAV258 (Varble laboratory collection) using primers ONV3/ONV4. The three PCR fragments were purified (Zymo kit) and used in a 1:1:1 molar ratio Golden Gate assembly reaction with AarI (ThermoFisher) and T4 ligase (NEB) for 50 cycles of 1.5 min at 37°C followed by 3 min at 16°C. Enzymes were inactivated at 80°C for 10 min. The assembly was purified (Zymo kit), and 1 µL was used as a template in a PCR using primers ONV1/ONV6. The resulting 3,995-bp fragment was purified (Zymo kit), and 10 µL was used to transform electrocompetent NV3 cells. Kanamycin-resistant colonies were selected and used for further analysis, resulting in strain NV4.

Strain NV6 (*hsdR::ery*, *cas9::tetM, tetR,* Ptet-*dcas9*) was constructed by amplifying approximately 1 kb upstream and downstream of the *cas9* locus using primers ONV1/ONV9 and ONV6/ONV12, respectively, using chromosomal DNA of strain NV1 as a template. The *tetM-tetR-Ptet-dcas9* cassette was amplified from chromosomal DNA of strain VL3469 (37) using primers ONV10/ONV11. The three PCR fragments were purified (Zymo kit) and used in a 1:1:1 molar ratio Golden Gate assembly reaction with AarI (ThermoFisher) and T4 ligase (NEB) for 60 cycles of 1.5 min at 37°C followed by 3 min at 16°C. Enzymes were inactivated at 80°C for 10 min. The 9,774-bp ligation product was cut from gel and purified (Zymoclean Gel DNA Recovery Kit) and directly used to transform electrocompetent NV4 cells. Tetracycline-resistant colonies were selected, and plasmid was cured, resulting in strain NV6. Since NV6 cells harbor the *tetM* resistance marker, growth is not perturbed by doxy upon inducing with 20 ng/mL.

Plasmid pDC-sgRNA was constructed as follows: a PCR using primers ONV21/ONV22 and plasmid pDC123 (24) as a template was performed to obtain the vector backbone. The *sgRNA-mCherry* cassette flanked by the Illumina read 1 and read 2 sequences was amplified using plasmid pVL4930 (Veening laboratory collection) as a template with primers ONV23/ONV24. Next, the two fragments were purified (Zymo kit) and used in a 1:1 molar ratio Golden Gate assembly reaction with BsaI-HF2 (NEB) and T4 ligase (NEB) for 50 cycles of 1.5 min at 37°C followed by 3 min at 16°C. Enzymes were inactivated at 80°C for 10 min. The ligation product was used to transform chemically competent *E. coli* MC1061 (MCLab). A pink, mCherry-expressing chloramphenicol-resistant colony was restreaked and selected for further analysis, resulting in *E. coli* strain pDC-sgRNA (Table 1). Plasmid pDC-sgRNA was purified (Qiagen Miniprep Kit) and verified by nanopore sequencing (Plasmidsaurus). Note that *mCherry*, and the subsequent sgRNA, is driven by the strong constitutive P3 promoter (43) and that all cloned sgRNAs will have adenine as initiating nucleotide (+1) (Fig. 2A), ensuring strong expression regardless of spacer sequence (41, 53).

To construct GAS strains NV19, NV22, NV25, and NV26, complementary oligos ONV60/ONV61, ONV66/ONV67, ONV72/ONV73, and ONV74/ONV75, respectively, were annealed

and phosphorylated. Briefly, 2.5 µL of each complementary oligo (at 100 µM concentration) was annealed in a 50 µL reaction containing 5 µL 10× TEN buffer (100 mM Tris-HCl pH 8, 10 mM EDTA, and 500 mM NaCl) for 5 min at 95°C and slowly cooled to room temperature. Next, 1 µL of the annealed oligos was phosphorylated in a 10 µL reaction containing 0.25 µL T4 PNK (10,000 units/mL, NEB) and 1 µL 10× T4 ligase buffer for 40 min at 37°C before heat inactivation at 65°C for 20 min. Finally, the phosphorylated annealed oligos were diluted 10-fold (to 0.05 µM DNA) ready to use for ligation. To generate the digested pDC-sgRNA vector, 1 µL of plasmid pDC-sgRNA was used as a template in a PCR using outward-facing primers ONV76/ONV77 binding within the *mCherry* sequence. The PCR product was incubated with EcoRV (NEB) that cuts inside *mCherry* for 30 min at 37°C to linearize any remaining template DNA. Next, the reaction was purified (Zymo kit) and digested with BsmBI-HF (NEB) at 55°C for 3 h followed by purification using the Zymo kit. A total of 100 ng of pure digested pDC-sgRNA was used in a 15 µL ligation reaction containing 3.5 µL of the 0.05 µM annealed phosphorylated primers. Ligation was performed for 1 h at RT or overnight at 16°C. Finally, 7 µL of the ligation mixture was used to transform electrocompetent cells of strain NV6 by electroporation, resulting in strains NV19, NV22, NV25, and NV26, respectively. Plasmids were isolated by miniprep (Qiagen), and correct spacer sequences were verified by Sanger sequencing using primer ONV92.

Microtiter plate-based growth assay

Overnight GAS cultures grown in THB medium at 37°C were diluted 1:20 in the morning in fresh THB until mid-exponential growth (OD_{600nm} = 0.3) with no inducer at 37°C, after which they were diluted to OD_{600nm} = 0.004 in 250 µL of fresh THB medium supplemented with doxy when appropriate inside 96-well flat bottom microtiter plates (Costar 3370) covered with Breath-Easy film (Sigma) to prevent evaporation. Cellular growth was then monitored every 10 min at 37°C in a microtiter plate reader (TECAN Infinite F200 Pro). Each growth assay was performed in triplicate, and the average of the triplicate values with standard errors of the mean was plotted using BactExtract (56).

DIC and fluorescence microscopy

GAS cells were grown in THB medium at 37°C to an OD_{600nm} = 0.3 without any inducer and diluted 50 times in fresh THB medium supplemented, when appropriate, with 20 ng·mL^{-1} doxy (for the activation of dCas9). After 3 h, 1 mL of culture was collected. For membrane staining, 5 µg·mL^{-1} of Nile red (Invitrogen) was added, and for DAPI staining, 1 µg·mL^{-1} DAPI (Sigma-Aldrich) was added to the cells and incubated for 5 min at room temperature prior to centrifugation. Cells were washed twice with 1 mL PBS and re-suspended into 50 µL PBS. A volume of 1 µL of cells was then spotted onto PBS agarose (1%) pads in 10-well multitest microscope slides (MP Biomedicals). Microscopy acquisition was performed using a Zeiss M1 upright microscope with a 100× oil-immersion objective. Images were processed using Fuji (57).

Genome sequencing, annotation, methylation analysis, and spacer design

Strain NV1 (GAS 5448, Nizet lab collection) was sequenced, assembled, and annotated by Plasmidsaurus, Inc. according to the protocols listed on the Plasmidsaurus website (https://www.plasmidsaurus.com/faq/#bact-assembly). In addition, strains NV1, NV28, and NV6 were also sequenced using the PacBio Sequel II instrument at the Lausanne Genomics Facility. Read demultiplexing and quality control were performed with SMRTLink version 11.0 (https://www.pacb.com/support/software-downloads/). The microbial genome assembly pipeline in this toolkit was used to assemble genomes and identify methylation motifs. Assemblies were circularized with circlator (58). Structural variants were detected with pbmm2 version 1.13.1 (59) and pbsv version 2.9.0 using default settings and then confirmed manually. Whole genome alignments were performed and visualized in Mauve (60). This revealed a large genome inversion of

1,475,033 bp. Prokka (25) was used to annotate the NV1 PacBio genome and design a unique sgRNA (see Table S1) for every genetic feature as described (41). Genome sequences confirmed correct gene replacement of *hsdR* in NV6 and NV28 and correct integration of Ptet-*dcas9* at the *cas9* locus in NV6. Besides the large genome inversion and several smaller insertions, the genome differs on the following sites from the publicly available 5448 genome sequence (26) (GenBank: CP008776.1): NV1 numbering: 196,187 t→c, 196,188 c→t, 196,385 g→t, 196,446 t→c, 196,452 t→c, 296,177 a→c, 296,508 g→t, 296,568 t→c, 296,575 t→c, 334,494 c→a, 334,434 a→g, 334,427 a→g, 1,308,897 g→a, 1,310,949 a→c, 1,518,946 g→a, 1,518,953 g→a, 1,519,013 a→c, 1,565,892 a→t, 1,599,979 a→c, 1,672,223 a→g, 1,672,224 g→a. These SNPs are mainly related to the ISAs1-like elements. The polished NV1 genome was further annotated by the NCBI Prokaryotic Genome Annotation Pipeline and is available with accession number CP140117.2 and visualized through SpyBrowse (see below).

SpyBrowse

SpyBrowse (https://veeninglab.com/SpyBrowse) is based on JBrowse 2 (13). Features were divided over three annotation tracks: (i) reference sequence, (ii) coding features, and (iii) designed sgRNAs. GC content is calculated via the NucContent plugin (available at https://github.com/jjrozewicki/jbrowse2-plugin-nuccontent). The NCBI annotation of *S. pyogenes* NV1 was used for the coding features track (accession: CP140117.2)

Quantifications and statistical analysis

Data analysis was performed using R (R version 4.2.2) and Prism (Version 10.0.3, GraphPad). Data shown are represented as the mean of at least three replicates ± SEM if data came from one experiment with replicated measurement and ±SD if data came from separate experiments.

Flow cytometry

NV25 (sgRNA-*emm*), NV26 (sgRNA-control), and M protein knockout GAS M1T1 (61) 5448 were grown overnight in THB with chloramphenicol for NV25 and NV26. Cultures were diluted 1:10 from overnight in THB (without chloramphenicol) and grown to the mid-logarithmic phase (OD_{600} = 0.4) for 2.5 h. During this time, NV25 and NV26 were grown ±20 ng/mL doxycycline to induce the CRISPRi system. Bacteria were washed in PBS and incubated in 10% donkey serum at room temperature. Rabbit M protein antisera (Vaxcyte) was added at 2% final concentration for 1 h at room temperature. Bacteria were washed with PBS and then incubated in 1:200 donkey anti-rabbit IgG-conjugated AlexaFluor 488 fluorophore (Thermo Fisher #21206) for 30 min at room temperature. Samples were washed in PBS and run on a BD FACSCalibur. Flow cytometry data were analyzed with FlowJo v. 10.8.2 (Tree Star, Inc.).

Mouse infection experiments

Eight-week-old female CD1 mice (Charles River Laboratories) were infected intraperitoneally with $1–3 \times 10^8$ CFU in 100 µL of each GAS engineered strain (*n* = 20 per strain). One hour prior to infection, mice were injected intraperitoneally with either 25 µg doxycycline (*n* = 10) or PBS (*n* = 10). At 48 h following infection, a second 25 µg doxy dose was administered I.P. Mortality was observed daily for 14 days post-infection. Mice were housed on a 12-h light/dark schedule, fed a 2020x diet (Envigo), and received acidified water. Prior to experimentation, mice were randomized into cages with no more than five mice per cage.

AUTHOR AFFILIATIONS

[1]Department of Pediatrics, University of California San Diego, La Jolla, California, USA
[2]Department of Fundamental Microbiology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
[3]Department of Oral Rehabilitation and Biosciences, School of Dentistry, Oregon Health & Science University, Portland, Oregon, USA
[4]Genomic Medicine Group, J. Craig Venter Institute, La Jolla, California, USA
[5]School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, New York, USA
[6]Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA

AUTHOR ORCIDs

Elisabet Bjånes http://orcid.org/0000-0002-2747-7699
Alexandra Stream http://orcid.org/0000-0003-0089-0552
Axel B. Janssen http://orcid.org/0000-0002-9865-447X
Jonathon L. Baker http://orcid.org/0000-0001-5378-322X
Victor Nizet http://orcid.org/0000-0003-3847-0422
Jan-Willem Veening http://orcid.org/0000-0002-3162-6634

AUTHOR CONTRIBUTIONS

Elisabet Bjånes, Conceptualization, Investigation, Methodology, Formal analysis, Writing – review and editing | Alexandra Stream, Investigation, Methodology, Formal analysis, Writing – review and editing | Axel B. Janssen, Software, Investigation, Formal analysis | Paddy S. Gibson, Investigation, Software, Formal analysis | Afonso M. Bravo, Investigation, Software, Formal analysis | Samira Dahesh, Investigation, Formal analysis | Jonathon L. Baker, Investigation, Formal analysis | Andrew Varble, Investigation, Formal analysis | Victor Nizet, Conceptualization, Formal analysis, Supervision, Writing – review and editing | Jan-Willem Veening, Conceptualization, Investigation, Methodology, Data curation, Formal analysis, Supervision, Writing – original draft, Writing – review and editing

DATA AVAILABILITY

The data that support the findings of this study are incorporated in the manuscript and its supporting information. PacBio genome sequences, assemblies, and sequencing reads are available at NCBI under BioProject accession number PRJNA1050251.

ETHICS APPROVAL

Mouse experiments were approved by the UC San Diego Institutional Animal Care and Use Committee (Protocol #S00227M) in compliance with federal regulations and were conducted with oversight from veterinary professionals.

ADDITIONAL FILES

The following material is available online.

Supplemental Material

Table S1 (mBio00840-24-s0001.xlsx). GAS 5448 (NV1) genome-wide sgRNA design.
Table S2 (mBio00840-24-s0002.xlsx). Oligonucleotides.

REFERENCES

1. Cole JN, Barnett TC, Nizet V, Walker MJ. 2011. Molecular insight into invasive group A streptococcal disease. Nat Rev Microbiol 9:724–736. https://doi.org/10.1038/nrmicro2648

2. Mitchell TJ. 2003. The pathogenesis of streptococcal infections: from tooth decay to meningitis. Nat Rev Microbiol 1:219–230. https://doi.org/10.1038/nrmicro771

3. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685–694. https://doi.org/10.1016/S1473-3099(05)70267-X

4. Ralph AP, Carapetis JR. 2013. Group A streptococcal diseases and their global burden. Curr Top Microbiol Immunol 368:1–27. https://doi.org/10.1007/82_2012_280

5. Sims Sanyahumbi A, Colquhoun S, Wyber R, Carapetis JR. 2016. Global disease burden of group A Streptococcus. In Ferretti JJ, Stevens DL, Fischetti VA (ed), Basic biology to clinical manifestations. University of Oklahoma Health Sciences Center, Oklahoma City (OK).

6. Johnson AF, LaRock CN. 2021. Antibiotic treatment, mechanisms for failure, and adjunctive therapies for infections by group A. Front Microbiol 12:760255. https://doi.org/10.3389/fmicb.2021.760255

7. Dale JB, Walker MJ. 2020. Update on group A streptococcal vaccine development. Curr Opin Infect Dis 33:244–250. https://doi.org/10.1097/QCO.0000000000000644

8. McMillan DJ, Drèze P-A, Vu T, Bessen DE, Guglielmini J, Steer AC, Carapetis JR, Van Melderen L, Sriprakash KS, Smeesters PR. 2013. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clin Microbiol Infect 19:E222–E229. https://doi.org/10.1111/1469-0691.12134

9. Aziz RK, Kotb M. 2008. Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis 14:1511–1517. https://doi.org/10.3201/eid1410.071660

10. Le Breton Y, McIver KS. 2013. Genetic manipulation of Streptococcus pyogenes (the group A Streptococcus, GAS). Curr Protoc Microbiol 30:9D.3.1-9D.3.29. https://doi.org/10.1002/9780471729259.mc09d03s30

11. Le Breton Y, Belew AT, Valdes KM, Islam E, Curry P, Tettelin H, Shirtliff ME, El-Sayed NM, McIver KS. 2015. Essential genes in the core genome of the human pathogen Streptococcus pyogenes. Sci Rep 5:9838. https://doi.org/10.1038/srep09838

12. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrby-Teglund A, Low DE, McGeer A, Kotb M. 2000. Genetic relatedness and superantigen expression in group A Streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun 68:3523–3534. https://doi.org/10.1128/IAI.68.6.3523-3534.2000

13. Diesh C, Stevens GJ, Xie P, De Jesus Martinez T, Hershberg EA, Leung A, Guo E, Dider S, Zhang J, Bridge C, Hogue G, Duncan A, Morgan M, Flores T, Bimber BN, Haw R, Cain S, Buels RM, Stein LD, Holmes IH. 2023. JBrowse 2: a modular genome browser with views of synteny and structural variation. Genome Biol 24:74. https://doi.org/10.1186/s13059-023-02914-z

14. Bateman A, Martin M-J, Orchard S, Magrane M, Ahmad S, Alpi E, Bowler-Barnett EH, Britto R, Bye-A-Jee H, Cukura A. 2023. UniProt: the universal protein knowledgebase in 2023. Nucleic Acids Res 51:D523–D531. https://doi.org/10.1093/nar/gkac1052

15. Price MN, Arkin AP. 2017. PaperBLAST: text mining papers for information about homologs. mSystems 2:e00039-17. https://doi.org/10.1128/mSystems.00039-17

16. Le Breton Y, Belew AT, Freiberg JA, Sundar GS, Islam E, Lieberman J, Shirtliff ME, Tettelin H, El-Sayed NM, McIver KS. 2017. Genome-wide discovery of novel M1T1 group A streptococcal determinants important for fitness and virulence during soft-tissue infection. PLoS Pathog 13:e1006584. https://doi.org/10.1371/journal.ppat.1006584

17. Brouwer S, Rivera-Hernandez T, Curren BF, Harbison-Price N, De Oliveira DMP, Jespersen MG, Davies MR, Walker MJ. 2023. Pathogenesis, epidemiology and control of Group A Streptococcus infection. Nat Rev Microbiol 21:431–447. https://doi.org/10.1038/s41579-023-00865-7

18. Le Breton Y, Mistry P, Valdes KM, Quigley J, Kumar N, Tettelin H, McIver KS. 2013. Genome-wide identification of genes required for fitness of group A Streptococcus in human blood. Infect Immun 81:862–875. https://doi.org/10.1128/IAI.00837-12

19. Finn MB, Ramsey KM, Tolliver HJ, Dove SL, Wessels MR. 2021. Improved transformation efficiency of group A Streptococcus by inactivation of a type I restriction modification system. PLoS One 16:e0248201. https://doi.org/10.1371/journal.pone.0248201

20. Nye TM, Jacob KM, Holley EK, Nevarez JM, Dawid S, Simmons LA, Watson Jr ME. 2019. DNA methylation from a type I restriction modification system influences gene expression and virulence in Streptococcus pyogenes. PLoS Pathog 15:e1007841. https://doi.org/10.1371/journal.ppat.1007841

21. DebRoy S, Shropshire WC, Tran CN, Hao H, Gohel M, Galloway-Peña J, Hanson B, Flores AR, Shelburne SA. 2021. Characterization of the type I restriction modification system broadly conserved among group A streptococci. mSphere 6:e0079921. https://doi.org/10.1128/mSphere.00799-21

22. Okada R, Matsumoto M, Zhang Y, Isaka M, Tatsuno I, Hasegawa T. 2014. Emergence of type I restriction modification system-negative emm1 type Streptococcus pyogenes clinical isolates in Japan. APMIS 122:914–921. https://doi.org/10.1111/apm.12230

23. Sorg RA, Gallay C, Van Maele L, Sirard J-C, Veening J-W. 2020. Synthetic gene-regulatory networks in the opportunistic human pathogen

Streptococcus pneumoniae. Proc Natl Acad Sci U S A 117:27608–27619. https://doi.org/10.1073/pnas.1920015117

24. Chaffin DO, Rubens CE. 1998. Blue/white screening of recombinant plasmids in Gram-positive bacteria by interruption of alkaline phosphatase gene (*phoZ*) expression. Gene 219:91–99. https://doi.org/10.1016/s0378-1119(98)00396-5

25. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068–2069. https://doi.org/10.1093/bioinformatics/btu153

26. Fiebig A, Loof TG, Babbar A, Itzek A, Koehorst JJ, Schaap PJ, Nitsche-Schmitz DP. 2015. Comparative genomics of *Streptococcus pyogenes* M1 isolates differing in virulence and propensity to cause systemic infection in mice. Int J Med Microbiol 305:532–543. https://doi.org/10.1016/j.ijmm.2015.06.002

27. Khazaal S, Al Safadi R, Osman D, Hiron A, Gilot P. 2020. Data on the link between genomic integration of IS*1548* and lineage of the strain obtained by bioinformatic analyses of sequenced genomes of *Streptococcus agalactiae* available at the National Center for Biotechnology Information database. Data Brief 28:105066. https://doi.org/10.1016/j.dib.2019.105066

28. Vigouroux A, Bikard D. 2020. CRISPR tools to control gene expression in bacteria. Microbiol Mol Biol Rev 84:e00077-19. https://doi.org/10.1128/MMBR.00077-19

29. Todor H, Silvis MR, Osadnik H, Gross CA. 2021. Bacterial CRISPR screens for gene function. Curr Opin Microbiol 59:102–109. https://doi.org/10.1016/j.mib.2020.11.005

30. Zhang R, Xu W, Shao S, Wang Q. 2021. Gene silencing through CRISPR interference in bacteria: current advances and future prospects. Front Microbiol 12:635227. https://doi.org/10.3389/fmicb.2021.635227

31. Call SN, Andrews LB. 2022. CRISPR-based approaches for gene regulation in non-model bacteria. Front Genome Ed 4:892304. https://doi.org/10.3389/fgeed.2022.892304

32. Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA. 2013. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res 41:7429–7437. https://doi.org/10.1093/nar/gkt520

33. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. 2013. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173–1183. https://doi.org/10.1016/j.cell.2013.02.022

34. Le Rhun A, Escalera-Maurer A, Bratovič M, Charpentier E. 2019. CRISPR-Cas in *Streptococcus pyogenes*. RNA Biol 16:380–389. https://doi.org/10.1080/15476286.2019.1582974

35. Geissendörfer M, Hillen W. 1990. Regulated expression of heterologous genes in *Bacillus subtilis* using the Tn*10* encoded tet regulatory elements. Appl Microbiol Biotechnol 33:657–663. https://doi.org/10.1007/BF00604933

36. Bugrysheva JV, Froehlich BJ, Freiberg JA, Scott JR. 2011. The histone-like protein Hlp is essential for growth of *Streptococcus pyogenes*: comparison of genetic approaches to study essential genes. Appl Environ Microbiol 77:4422–4428. https://doi.org/10.1128/AEM.00554-11

37. Liu X, Kimmey JM, Matarazzo L, de Bakker V, Van Maele L, Sirard J-C, Nizet V, Veening J-W. 2021. Exploration of bacterial bottlenecks and *Streptococcus pneumoniae* pathogenesis by CRISPRi-Seq. Cell Host Microbe 29:107–120. https://doi.org/10.1016/j.chom.2020.10.001

38. Redelsperger IM, Taldone T, Riedel ER, Lepherd ML, Lipman NS, Wolf FR. 2016. Stability of doxycycline in feed and water and minimal effective doses in tetracycline-inducible systems. J Am Assoc Lab Anim Sci 55:467–474.

39. Liu X, Van Maele L, Matarazzo L, Soulard D, Alves Duarte da Silva V, de Bakker V, Dénéréaz J, Bock FP, Taschner M, Ou J, Gruber S, Nizet V, Sirard J-C, Veening J-W. 2024. A conserved antigen induces respiratory Th17-mediated broad serotype protection against pneumococcal superinfection. Cell Host Microbe 32:304–314. https://doi.org/10.1016/j.chom.2024.02.002

40. Lacks SA, Lopez P, Greenberg B, Espinosa M. 1986. Identification and analysis of genes for tetracycline resistance and replication functions in the broad-host-range plasmid pLS1. J Mol Biol 192:753–765. https://doi.org/10.1016/0022-2836(86)90026-4

41. de Bakker V, Liu X, Bravo AM, Veening J-W. 2022. CRISPRi-seq for genome-wide fitness quantification in bacteria. Nat Protoc 17:252–281. https://doi.org/10.1038/s41596-021-00639-6

42. van Gestel J, Hawkins JS, Todor H, Gross CA. 2021. Computational pipeline for designing guide RNAs for mismatch-CRISPRi. STAR Protoc 2:100521. https://doi.org/10.1016/j.xpro.2021.100521

43. Sorg RA, Kuipers OP, Veening J-W. 2015. Gene expression platform for synthetic biology in the human pathogen *Streptococcus pneumoniae*. ACS Synth Biol 4:228–239. https://doi.org/10.1021/sb500229s

44. White ML, Eswara PJ. 2021. *ylm* has more than a (Z Anchor) ring to it! J Bacteriol 203:e00460-20. https://doi.org/10.1128%2FJB.00460-20

45. Kifayat S, Yele V, Ashames A, Sigalapalli DK, Bhandare RR, Shaik AB, Nasipireddy V, Sanapalli BKR. 2023. Filamentous temperature sensitive mutant Z: a putative target to combat antibacterial resistance. RSC Adv 13:11368–11384. https://doi.org/10.1039/d3ra00013c

46. Haydon DJ, Stokes NR, Ure R, Galbraith G, Bennett JM, Brown DR, Baker PJ, Barynin VV, Rice DW, Sedelnikova SE, Heal JR, Sheridan JM, Aiwale ST, Chauhan PK, Srivastava A, Taneja A, Collins I, Errington J, Czaplewski LG. 2008. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 321:1673–1675. https://doi.org/10.1126/science.1159961

47. Alves J, Rand JD, Johnston ABE, Bowen C, Lynskey NN. 2023. Methylome-dependent transformation of *emm*1 group A streptococci. mBio 14:e0079823. https://doi.org/10.1128/mbio.00798-23

48. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, Henningham A, McArthur JD, Dinkla K, Aziz RK, Kansal RG, Simpson AJ, Buchanan JT, Chhatwal GS, Kotb M, Nizet V. 2007. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 13:981–985. https://doi.org/10.1038/nm1612

49. Liu X, Gallay C, Kjos M, Domenech A, Slager J, van Kessel SP, Knoops K, Sorg RA, Zhang J-R, Veening J-W. 2017. High-throughput CRISPRi phenotyping identifies new essential genes in *Streptococcus pneumoniae*. Mol Syst Biol 13:931. https://doi.org/10.15252/msb.20167449

50. Zhu L, Charbonneau ARL, Waller AS, Olsen RJ, Beres SB, Musser JM. 2017. Novel genes required for the fitness of *Streptococcus pyogenes* in human saliva. mSphere 2:e00460-17. https://doi.org/10.1128/mSphereDirect.00460-17

51. Michna RH, Zhu B, Mäder U, Stülke J. 2016. SubtiWiki 2.0--an integrated database for the model organism *Bacillus subtilis*. Nucleic Acids Res 44:D654–D662. https://doi.org/10.1093/nar/gkv1006

52. Keseler IM, Mackie A, Santos-Zavaleta A, Billington R, Bonavides-Martínez C, Caspi R, Fulcher C, Gama-Castro S, Kothari A, Krummenacker M, Latendresse M, Muñiz-Rascado L, Ong Q, Paley S, Peralta-Gil M, Subhraveti P, Velázquez-Ramírez DA, Weaver D, Collado-Vides J, Paulsen I, Karp PD. 2017. The EcoCyc database: reflecting new knowledge about *Escherichia coli* K-12. Nucleic Acids Res 45:D543–D550. https://doi.org/10.1093/nar/gkw1003

53. Slager J, Aprianto R, Veening J-W. 2018. Deep genome annotation of the opportunistic human pathogen *Streptococcus pneumoniae* D39. Nucleic Acids Res 46:9971–9989. https://doi.org/10.1093/nar/gky725

54. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al. 2021. Highly accurate protein structure prediction with AlphaFold. Nature 596:583–589. https://doi.org/10.1038/s41586-021-03819-2

55. Rueff A-S, van Raaphorst R, Aggarwal SD, Santos-Moreno J, Laloux G, Schaerli Y, Weiser JN, Veening J-W. 2023. Synthetic genetic oscillators demonstrate the functional importance of phenotypic variation in pneumococcal-host interactions. Nat Commun 14:7454. https://doi.org/10.1038/s41467-023-43241-y

56. Dénéréaz J, Veening J-W. 2024. BactEXTRACT: an R Shiny app to quickly extract, plot and analyse bacterial growth and gene expression data. Access Microbiol 6:000742.v3. https://doi.org/10.1099/acmi.0.000742.v3

57. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676–682. https://doi.org/10.1038/nmeth.2019

58. Hunt M, Silva ND, Otto TD, Parkhill J, Keane JA, Harris SR. 2015. Circlator: automated circularization of genome assemblies using long sequencing reads. Genome Biol 16:294. https://doi.org/10.1186/s13059-015-0849-0

59. GitHub. PacificBiosciences/pbmm2: a minimap2 frontend for PacBio native data formats. GitHub. Available from: https://github.com/PacificBiosciences/pbmm2. Retrieved 16 Dec 2023.

60. Darling AE, Tritt A, Eisen JA, Facciotti MT. 2011. Mauve assembly metrics. Bioinformatics 27:2756–2757. https://doi.org/10.1093/bioinformatics/btr451

61. Lauth X, von Köckritz-Blickwede M, McNamara CW, Myskowski S, Zinkernagel AS, Beall B, Ghosh P, Gallo RL, Nizet V. 2009. M1 protein allows group A streptococcal survival in phagocyte extracellular traps through cathelicidin inhibition. J Innate Immun 1:202–214. https://doi.org/10.1159/000203645